Please login to the form below

Not currently logged in
Email:
Password:

Positive results in Sanofi RA trial

Sarilumab, developed by Sanofi and Regeneron, has shown positive results for the treatment of rheumatoid arthritis in a phase IIb trial, although the drug failed to show great benefit in ankylosing spondylitis patients

Sarilumab, developed by Sanofi and Regeneron, has shown positive results in a phase IIb trial concerning the drug's safety and efficacy in treating rheumatoid arthritis, although the drug failed to show great benefit in ankylosing spondylitis (AS) patients.

According to Sanofi, the MOBILITY study, involving 306 participants, demonstrated that patients treated with sarilumab in combination with a standard RA treatment, methotrexate (MTX), achieved a significant improvement in signs and symptoms of moderate-to-severe RA compared to patients treated with MTX alone.

However, when used as a treatment for AS, significant improvement was not demonstrated when compared to placebo, although the drug was well-tolerated.

"Following these encouraging phase IIb results in rheumatoid arthritis, the companies are currently discussing the dose(s) of sarilumab to advance into the phase III portion of the MOBILITY trial," said Elias Zerhouni, president, global research & development, Sanofi.

13th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics